数据表1：阿来替尼用于中国早期ALK阳性非小细胞肺癌术后辅助治疗的长期避免复发和复发相关成本

数据集获取（Figshare）

• 源站标题：Data Sheet 1_The long-term avoided recurrences and recurrence-related cost of alectinib for postoperative adjuvant therapy in Chinese patients with early-stage ALK-positive non-small cell lung cancer.pdf
• DOI：10.3389/fpubh.2025.1571980.s001
• 发布日期：2026-02-05
• 文件数：1 个
• 文件总体积：894.25 KB
• 源站页面：https://frontiersin.figshare.com/articles/dataset/Data_Sheet_1_The_long-term_avoided_recurrences_and_recurrence-related_cost_of_alectinib_for_postoperative_adjuvant_therapy_in_Chinese_patients_with_early-stage_ALK-positive_non-small_cell_lung_cancer_pdf/31260955

命令行下载

curl -L -o "Data Sheet 1_The long-term avoided recurrences and recurrence-related cost of alectinib for postoperative adjuvant therapy in Chinese patients with ea.pdf" "https://ndownloader.figshare.com/files/61653694"

文件清单

• Data Sheet 1_The long-term avoided recurrences and recurrence-related cost of alectinib for postoperative adjuvant therapy in Chinese patients with ea.pdf（894.25 KB）

文件总体积 894.25 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

AimsAlectinib was approved by the US, Europe and China in 2024 as the first adjuvant targeted therapy for ALK+ NSCLC, lowering risk of disease recurrence or death by 76%. Alectinib addresses a critical gap in postoperative adjuvant therapy for ALK+ NSCLC. From Chinese healthcare-system perspective, this study evaluates the impact of introducing alectinib in adjuvant therapy for stage IB (tumor ≥ 4 cm) to IIIA (UICC/AJCC 7th edition) ALK+ NSCLC on prevention of recurrence and the associated direct medical costs, compared to platinum-based chemotherapy.
MethodsA Markov model was developed to estimate the number of locoregional and metastatic recurrences over a 10-year period by defining four health states: disease-free survival, locoregional recurrence, metastatic recurrence, and death. In the control group, all patients received platinum-based chemotherapy, while in the intervention group, 75% received alectinib and 25% received platinum-based chemotherapy. Clinical data were collected from open-label, randomized phase 3 trials ALINA and ALEX. Cost parameters were derived from local charges, expert consultation, and published literature.
ResultsCompared to control group, the intervention group would reduce recurrences by 11,300 cases over 10 years, including 3,684 locoregional and 7,616 metastatic cases. This corresponds to a 45.82% lower recurrence rate. Estimated recurrence-related cost savings amounted to 6.910 billion RMB, with 1.445 billion RMB saved from locoregional recurrences and 5.465 billion RMB from metastatic recurrences. This represents a 41.49% reduction in costs compared to control group. These findings were robust across various scenario analyses.
ConclusionUsing alectinib in postoperative adjuvant therapy significantly reduces both the recurrence rate and recurrence-related treatment costs for stage IB (tumor ≥ 4 cm) to IIIA ALK+ NSCLC patients, compared to platinum-based chemotherapy. From perspective of Chinese healthcare system, this approach shows substantial potential for preventing recurrence and achieving cost savings.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.3389/fpubh.2025.1571980.s001（source: https://frontiersin.figshare.com/articles/dataset/Data_Sheet_1_The_long-term_avoided_recurrences_and_recurrence-related_cost_of_alectinib_for_postoperative_adjuvant_therapy_in_Chinese_patients_with_early-stage_ALK-positive_non-small_cell_lung_cancer_pdf/31260955）。